脓毒症合并房颤患者去氧肾上腺素与去甲肾上腺素起始后心率比较
该研究利用大型数据库纳入脓毒症合并房颤患者1847例,比较去氧肾上腺素(901例,49%)与去甲肾上腺素(946例,51%)起始后1小时和6小时的心率差异。多变量调整线性回归显示,去氧肾上腺素与1小时心率较低相关(-4次/分;95%CI,-6至-1;P<.001)及6小时心率较低相关(-4次/分;95%CI,-6至-1;P=.004)。基线心率越高,去氧肾上腺素相比去甲肾上腺素的心率下降幅度越大。次要结局(转复窦性心律、心动过缓、升压药持续时间、ICU及住院时间、住院死亡)无差异。作者认为心率轻度降低是否与临床结局相关需进一步研究。
要点
- 脓毒症合并房颤患者中,去氧肾上腺素起始后1小时心率较去甲肾上腺素低4次/分(95%CI -6至-1;P<.001)。
- 6小时心率同样低4次/分(95%CI -6至-1;P=.004)。
- 基线心率越高,去氧肾上腺素相比去甲肾上腺素的心率下降幅度越大。
- 次要结局(转复窦性心律、心动过缓、升压药持续时间、ICU及住院时间、住院死亡)无差异。
- 作者认为心率轻度降低是否与临床结局相关需进一步研究。
适用人群与场景
- 脓毒症合并房颤、起始去甲肾上腺素或去氧肾上腺素的患者。
诊断标准与关键阈值
- 按基线心率分层:≥110次/分或<110次/分。
研究设计与关键结果
- 研究类型:利用大型数据库的回顾性队列研究(原文未明确单中心或多中心);样本量1847例脓毒症合并房颤患者;去甲肾上腺素组946例(51%),去氧肾上腺素组901例(49%)。
- 主要终点:多变量调整后,去氧肾上腺素与1小时心率较低相关(-4次/分;95%CI,-6至-1;P<.001),6小时心率较低相关(-4次/分;95%CI,-6至-1;P=.004)。
- 效应修饰:升压药前心率越高,去氧肾上腺素相比去甲肾上腺素的心率下降幅度越大。
- 次要终点:转复窦性心律、心动过缓、升压药持续时间、ICU及住院时间、住院死亡均无差异。
- 探索性分析和敏感性分析(中断时间序列)结果相似。
证据类型、等级与局限
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在脓毒症合并房颤患者中,去氧肾上腺素起始与去甲肾上腺素相比心率轻度降低,心率在升压药起始时是重要的效应修饰因素;心率轻度降低是否与临床结局相关需进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Atrial fibrillation (AF) is a common complication of sepsis. It is unclear whether norepinephrine, an α- and β-agonist, and phenylephrine, an α-agonist, are associated with different heart rates among patients with sepsis and AF.
RESEARCH QUESTION: Among patients with sepsis and AF, what is the difference in heart rate after phenylephrine initiation vs norepinephrine initiation?
STUDY DESIGN AND METHODS: With the use of an extensive database, we identified patients with sepsis and AF at the time of norepinephrine or phenylephrine initiation. We estimated the difference in heart rate between patients who received phenylephrine or norepinephrine 1 and 6 h after vasopressor initiation with the use of multivariable-adjusted linear regression, tested for effect modification by heart rate, and stratified by baseline heart rate ≥ 110 or < 110 beats/min. Secondary outcomes included conversion to sinus rhythm, bradycardia, vasopressor duration, ICU and hospital length of stay, and hospital death. Exploratory analyses were adjusted for practices that occurred after vasopressor initiation; sensitivity analyses used interrupted time series to estimate the difference in average heart rate between patients who received phenylephrine or norepinephrine.
RESULTS: Among 1847 patients with sepsis and AF, 946 patients (51%) received norepinephrine, and 901 patients (49%) received phenylephrine. After multivariable adjustment, phenylephrine was associated with a lower heart rate at 1 h (-4 beats/min; 95% CI, -6 to -1; P < .001) and 6 h (-4 beats/min; 95% CI, -6 to -1; P = .004). Higher heart rate before vasopressor administration was associated with larger heart rate reduction in patients who received phenylephrine compared with norepinephrine. There were no differences in secondary outcomes. Results were similar in exploratory and sensitivity analyses.
INTERPRETATION: In patients with sepsis and AF, the initiation of phenylephrine was associated with modestly lower heart rate compared with norepinephrine. Heart rate at vasopressor initiation appeared to be an important effect modifier. Whether modest reductions in heart rate are associated with clinical outcomes requires further study.
参考来源
- Law AC, Bosch NA, Peterson D, et al. Comparison of Heart Rate After Phenylephrine vs Norepinephrine Initiation in Patients With Septic Shock and Atrial Fibrillation. Chest. 2022. PMID: 35526604. doi:10.1016/j.chest.2022.04.147
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。